Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic Adipose-Derived Mesenchymal Stem Cells on Fibrin-Hyaluronic Matrix for Venous Leg Ulcers
2024-513151-33-00Phase 2Suspended
- Sponsor
- Andalusian Progress and Health Public Foundation
- Start
- Apr 2024
- Modality
- Tissue Cells → Other Cell Types → Cell Therapies, Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of Bioengineered Artificial Mesenchymal Sheet in stasis ulcer (2 arms), sponsored by Andalusian Progress and Health Public Foundation. Primary endpoint: Feasibility and safety of BAMS in venous leg ulcers. Started Apr 2024; status: suspended.
02
Drugs
Bioengineered Artificial Mesenchymal Sheet
03
Conditions
stasis ulcer
Beyond the preview
Go deeper on 2024-513151-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513151-33-00.